<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37626615</PMID><DateRevised><Year>2023</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9059</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>27</Day></PubDate></JournalIssue><Title>Biomedicines</Title><ISOAbbreviation>Biomedicines</ISOAbbreviation></Journal><ArticleTitle>Renin-Angiotensin System Components and Arachidonic Acid Metabolites as Biomarkers of COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2118</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines11082118</ELocationID><Abstract><AbstractText>Through the ACE2, a main enzyme of the renin-angiotensin system (RAS), SARS-CoV-2 gains access into the cell, resulting in different complications which may extend beyond the RAS and impact the Arachidonic Acid (ArA) pathway. The contribution of the RAS through ArA pathways metabolites in the pathogenesis of COVID-19 is unknown. We investigated whether RAS components and ArA metabolites can be considered biomarkers of COVID-19. We measured the plasma levels of RAS and ArA metabolites using an LC-MS/MS. Results indicate that Ang 1-7 levels were significantly lower, whereas Ang II levels were higher in the COVID-19 patients than in healthy control individuals. The ratio of Ang 1-7/Ang II as an indicator of the RAS classical and protective arms balance was dramatically lower in COVID-19 patients. There was no significant increase in inflammatory 19-HETE and 20-HETE levels. The concentration of EETs was significantly increased in COVID-19 patients, whereas the DHETs concentration was repressed. Their plasma levels were correlated with Ang II concentration in COVID-19 patients. In conclusion, evaluating the RAS and ArA pathway biomarkers could provide helpful information for the early detection of high-risk groups, avoid delayed medical attention, facilitate resource allocation, and improve patient clinical outcomes to prevent long COVID incidence.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghimire</LastName><ForeName>Biwash</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-9440-9058</Identifier><AffiliationInfo><Affiliation>College of Pharmacy, Idaho State University, Pocatello, ID 83209, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pour</LastName><ForeName>Sana Khajeh</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Idaho State University, Pocatello, ID 83209, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Middleton</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Utah, Salt Lake City, UT 84112, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division ofHematology, University of Utah, Salt Lake City, UT 84112, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nies</LastName><ForeName>Mary A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>College of Health, School of Nursing, Idaho State University, Pocatello, ID 83209, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aghazadeh-Habashi</LastName><ForeName>Ali</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4456-3123</Identifier><AffiliationInfo><Affiliation>College of Pharmacy, Idaho State University, Pocatello, ID 83209, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Office for Research Internal Small Grant Program</GrantID><Agency>Idaho State University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomedicines</MedlineTA><NlmUniqueID>101691304</NlmUniqueID><ISSNLinking>2227-9059</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">arachidonic acid</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">renin&#x2013;angiotensin system</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>26</Day><Hour>10</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>26</Day><Hour>10</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>26</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37626615</ArticleId><ArticleId IdType="pmc">PMC10452267</ArticleId><ArticleId IdType="doi">10.3390/biomedicines11082118</ArticleId><ArticleId IdType="pii">biomedicines11082118</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jackson C.B., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022;23:3&#x2013;20. doi: 10.1038/s41580-021-00418-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornilov S.A., Lucas I., Jade K., Dai C.L., Lovejoy J.C., Magis A.T. Plasma levels of soluble ACE2are associated with sex, Metabolic Syndrome, and its biomarkers in a large cohort, pointing to a possible mechanism for increased severity in COVID-19. Crit. Care. 2020;24:452. doi: 10.1186/s13054-020-03141-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03141-9</ArticleId><ArticleId IdType="pmc">PMC7373836</ArticleId><ArticleId IdType="pubmed">32698840</ArticleId></ArticleIdList></Reference><Reference><Citation>Oudit G.Y., Pfeffer M.A. Plasma angiotensin-converting enzyme 2: Novel biomarker in heart failure with implications for COVID-19. Eur. Heart J. 2020;41:1818&#x2013;1820. doi: 10.1093/eurheartj/ehaa414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa414</ArticleId><ArticleId IdType="pmc">PMC7224688</ArticleId><ArticleId IdType="pubmed">32388547</ArticleId></ArticleIdList></Reference><Reference><Citation>Khajeh Pour S., Scoville C., Tavernier S.S., Aghazadeh-Habashi A. Plasma angiotensin peptides as biomarkers of rheumatoid arthritis are correlated with anti-ACE2 auto-antibodies level and disease intensity. Inflammopharmacology. 2022;30:1295&#x2013;1302. doi: 10.1007/s10787-022-01008-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-022-01008-9</ArticleId><ArticleId IdType="pmc">PMC9134980</ArticleId><ArticleId IdType="pubmed">35618976</ArticleId></ArticleIdList></Reference><Reference><Citation>Soro-Paavonen A., Gordin D., Forsblom C., Rosengard-Barlund M., Waden J., Thorn L., Sandholm N., Thomas M.C., Groop P.-H., on behalf of the FinnDiane Study Group Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J. Hypertens. 2012;30:375&#x2013;383. doi: 10.1097/HJH.0b013e32834f04b6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0b013e32834f04b6</ArticleId><ArticleId IdType="pubmed">22179088</ArticleId></ArticleIdList></Reference><Reference><Citation>Varagic J., Ahmad S., Nagata S., Ferrario C.M. ACE2: Angiotensin II/Angiotensin-(1&#x2013;7) Balance in Cardiac and Renal Injury. Curr. Hypertens. Rep. 2014;16:420. doi: 10.1007/s11906-014-0420-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11906-014-0420-5</ArticleId><ArticleId IdType="pmc">PMC4286874</ArticleId><ArticleId IdType="pubmed">24510672</ArticleId></ArticleIdList></Reference><Reference><Citation>Dzau V.J. Tissue Angiotensin and Pathobiology of Vascular Disease. Hypertension. 2001;37:1047&#x2013;1052. doi: 10.1161/01.HYP.37.4.1047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.HYP.37.4.1047</ArticleId><ArticleId IdType="pubmed">11304501</ArticleId></ArticleIdList></Reference><Reference><Citation>Coto E., Avanzas P., G&#xf3;mez J. The Renin&#x2013;Angiotensin&#x2013;Aldosterone System and Coronavirus Disease 2019. Eur. Cardiol. Rev. 2021;16:e07. doi: 10.15420/ecr.2020.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.15420/ecr.2020.30</ArticleId><ArticleId IdType="pmc">PMC7967817</ArticleId><ArticleId IdType="pubmed">33737961</ArticleId></ArticleIdList></Reference><Reference><Citation>Souza dos Santos R.A., Passaglio K.T., Pesquero J.B., Bader M., Sim&#xf5;es e Silva A.C. Interactions Between Angiotensin-(1-7), Kinins, and Angiotensin II in Kidney and Blood Vessels. Hypertension. 2001;38:660&#x2013;664. doi: 10.1161/01.HYP.38.3.660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.HYP.38.3.660</ArticleId><ArticleId IdType="pubmed">11566951</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmudpour M., Roozbeh J., Keshavarz M., Farrokhi S., Nabipour I. COVID-19 cytokine storm: The anger of inflammation. Cytokine. 2020;133:155151. doi: 10.1016/j.cyto.2020.155151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2020.155151</ArticleId><ArticleId IdType="pmc">PMC7260598</ArticleId><ArticleId IdType="pubmed">32544563</ArticleId></ArticleIdList></Reference><Reference><Citation>South A.M., Brady T.M., Flynn J.T. ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic. Hypertension. 2020;76:16&#x2013;22. doi: 10.1161/HYPERTENSIONAHA.120.15291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.15291</ArticleId><ArticleId IdType="pmc">PMC7289676</ArticleId><ArticleId IdType="pubmed">32367746</ArticleId></ArticleIdList></Reference><Reference><Citation>Das U.N. Arachidonic acid in health and disease with focus on hypertension and diabetes mellitus: A review. J. Adv. Res. 2018;11:43&#x2013;55. doi: 10.1016/j.jare.2018.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jare.2018.01.002</ArticleId><ArticleId IdType="pmc">PMC6052660</ArticleId><ArticleId IdType="pubmed">30034875</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuelsson B. Arachidonic acid metabolism: Role in inflammation. Z. Rheumatol. 1991;50((Suppl. S1)):3&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1907059</ArticleId></ArticleIdList></Reference><Reference><Citation>Panigrahy D., Kaipainen A., Greene E.R., Huang S. Cytochrome P450-derived eicosanoids: The neglected pathway in cancer. Cancer Metastasis Rev. 2010;29:723&#x2013;735. doi: 10.1007/s10555-010-9264-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10555-010-9264-x</ArticleId><ArticleId IdType="pmc">PMC2962793</ArticleId><ArticleId IdType="pubmed">20941528</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldman M., Peterson S.J., Arad M., Hochhauser E. The role of 20-HETE in cardiovascular diseases and its risk factors. Prostaglandins Other Lipid Mediat. 2016;125:108&#x2013;117. doi: 10.1016/j.prostaglandins.2016.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prostaglandins.2016.05.007</ArticleId><ArticleId IdType="pubmed">27287720</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross G.J., Hsu A., Falck J.R., Nithipatikom K. Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts. J. Mol. Cell. Cardiol. 2007;42:687&#x2013;691. doi: 10.1016/j.yjmcc.2006.11.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2006.11.020</ArticleId><ArticleId IdType="pmc">PMC1876789</ArticleId><ArticleId IdType="pubmed">17217955</ArticleId></ArticleIdList></Reference><Reference><Citation>Asghar W., Aghazadeh-Habashi A., Jamali F. Cardiovascular effect of inflammation and nonsteroidal anti-inflammatory drugs on renin-angiotensin system in experimental arthritis. Inflammopharmacology. 2017;25:543&#x2013;553. doi: 10.1007/s10787-017-0344-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-017-0344-1</ArticleId><ArticleId IdType="pubmed">28389995</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghazadeh-Habashi A., Asghar W., Jamali F. Drug-Disease Interaction: Effect of Inflammation and Nonsteroidal Anti-Inflammatory Drugs on Cytochrome P450 Metabolites of Arachidonic Acid. J Pharm Sci. 2018;107:756&#x2013;763. doi: 10.1016/j.xphs.2017.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2017.09.020</ArticleId><ArticleId IdType="pubmed">28989019</ArticleId></ArticleIdList></Reference><Reference><Citation>Touyz R.M., Berry C. Recent advances in angiotensin II signaling. Braz. J. Med. Biol. Res. 2002;35:1001&#x2013;1015. doi: 10.1590/S0100-879X2002000900001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0100-879X2002000900001</ArticleId><ArticleId IdType="pubmed">12219172</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.C., Gupta T., Garcia V., Ding Y., Schwartzman M.L. 20-HETE and blood pressure regulation: Clinical implications. Cardiol. Rev. 2014;22:1&#x2013;12. doi: 10.1097/CRD.0b013e3182961659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CRD.0b013e3182961659</ArticleId><ArticleId IdType="pmc">PMC4292790</ArticleId><ArticleId IdType="pubmed">23584425</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoxha M. What about COVID-19 and arachidonic acid pathway? Eur. J. Clin. Pharmacol. 2020;76:1501&#x2013;1504. doi: 10.1007/s00228-020-02941-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-020-02941-w</ArticleId><ArticleId IdType="pmc">PMC7314570</ArticleId><ArticleId IdType="pubmed">32583353</ArticleId></ArticleIdList></Reference><Reference><Citation>La Vignera S., Cannarella R., Condorelli R.A., Torre F., Aversa A., Calogero A.E. Sex-Specific SARS-CoV-2 Mortality: Among Hormone-Modulated ACE2 Expression, Risk of Venous Thromboembolism and Hypovitaminosis D. Int. J. Mol. Sci. 2020;21:2948. doi: 10.3390/ijms21082948.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21082948</ArticleId><ArticleId IdType="pmc">PMC7215653</ArticleId><ArticleId IdType="pubmed">32331343</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebhard C., Regitz-Zagrosek V., Neuhauser H.K., Morgan R., Klein S.L. Impact of sex and gender on COVID-19 outcomes in Europe. Biol. Sex Differ. 2020;11:29. doi: 10.1186/s13293-020-00304-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13293-020-00304-9</ArticleId><ArticleId IdType="pmc">PMC7247289</ArticleId><ArticleId IdType="pubmed">32450906</ArticleId></ArticleIdList></Reference><Reference><Citation>Mjaess G., Karam A., Aoun F., Albisinni S., Roumegu&#xe8;re T. COVID-19 and the male susceptibility: The role of ACE2, TMPRSS2 and the androgen receptor. Prog. Urol. 2020;30:484&#x2013;487. doi: 10.1016/j.purol.2020.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.purol.2020.05.007</ArticleId><ArticleId IdType="pmc">PMC7242948</ArticleId><ArticleId IdType="pubmed">32620366</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin B., Ferguson C., White J.T., Wang S., Vessella R., True L.D., Hood L., Nelson P.S. Prostate-localized and Androgen-regulated Expression of the Membrane-bound Serine Protease TMPRSS21. Cancer Res. 1999;59:4180&#x2013;4184.</Citation><ArticleIdList><ArticleId IdType="pubmed">10485450</ArticleId></ArticleIdList></Reference><Reference><Citation>Song H., Seddighzadeh B., Cooperberg M.R., Huang F.W. Expression of ACE2, the SARS-CoV-2 Receptor, and TMPRSS2 in Prostate Epithelial Cells. Eur. Urol. 2020;78:296&#x2013;298. doi: 10.1016/j.eururo.2020.04.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2020.04.065</ArticleId><ArticleId IdType="pmc">PMC7200365</ArticleId><ArticleId IdType="pubmed">32418620</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalpiaz P.L., Lamas A.Z., Caliman I.F., Ribeiro R.F., Jr., Abreu G.R., Moyses M.R., Andrade T.U., Gouvea S.A., Alves M.F., Carmona A.K., et al. Sex Hormones Promote Opposite Effects on ACE and ACE2 Activity, Hypertrophy and Cardiac Contractility in Spontaneously Hypertensive Rats. PLoS ONE. 2015;10:e0127515. doi: 10.1371/journal.pone.0127515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0127515</ArticleId><ArticleId IdType="pmc">PMC4444272</ArticleId><ArticleId IdType="pubmed">26010093</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupte M., Thatcher S.E., Boustany-Kari C.M., Shoemaker R., Yiannikouris F., Zhang X., Karounos M., Cassis L.A. Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice. Arterioscler. Thromb. Vasc. Biol. 2012;32:1392&#x2013;1399. doi: 10.1161/ATVBAHA.112.248559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.112.248559</ArticleId><ArticleId IdType="pmc">PMC3355213</ArticleId><ArticleId IdType="pubmed">22460555</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupte M., Boustany-Kari C.M., Bharadwaj K., Police S., Thatcher S., Gong M.C., English V.L., Cassis L.A. ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008;295:R781&#x2013;R788. doi: 10.1152/ajpregu.00183.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpregu.00183.2008</ArticleId><ArticleId IdType="pmc">PMC2536864</ArticleId><ArticleId IdType="pubmed">18650320</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji H., Menini S., Zheng W., Pesce C., Wu X., Sandberg K. Role of angiotensin-converting enzyme 2 and angiotensin(1-7) in 17beta-oestradiol regulation of renal pathology in renal wrap hypertension in rats. Exp. Physiol. 2008;93:648&#x2013;657. doi: 10.1113/expphysiol.2007.041392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/expphysiol.2007.041392</ArticleId><ArticleId IdType="pubmed">18296494</ArticleId></ArticleIdList></Reference><Reference><Citation>Risk for COVID-19 Infection, Hospitalization, and Death by Age Group.  [(accessed on 14 June 2023)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html.</Citation></Reference><Reference><Citation>Kompaniyets L., Goodman A.B., Belay B., Freedman D.S., Sucosky M.S., Lange S.J., Gundlapalli A.V., Boehmer T.K., Blanck H.M. Body Mass Index and Risk for COVID-19-Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death&#x2013;United States, March&#x2013;December 2020. MMWR Morb. Mortal. Wkly. Rep. 2021;70:355&#x2013;361. doi: 10.15585/mmwr.mm7010e4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7010e4</ArticleId><ArticleId IdType="pmc">PMC7951819</ArticleId><ArticleId IdType="pubmed">33705371</ArticleId></ArticleIdList></Reference><Reference><Citation>Obesity, Race/Ethnicity, and COVID-19.  [(accessed on 14 June 2023)]; Available online:  https://www.cdc.gov/obesity/data/obesity-and-covid-19.html.</Citation></Reference><Reference><Citation>Cui L., Nithipatikom K., Campbell W.B. Simultaneous analysis of angiotensin peptides by LC&#x2013;MS and LC&#x2013;MS/MS: Metabolism by bovine adrenal endothelial cells. Anal. Biochem. 2007;369:27&#x2013;33. doi: 10.1016/j.ab.2007.06.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ab.2007.06.045</ArticleId><ArticleId IdType="pmc">PMC2754136</ArticleId><ArticleId IdType="pubmed">17681269</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranjit A., Khajeh Pour S., Aghazadeh-Habashi A. Bone-Targeted Delivery of Novokinin as an Alternative Treatment Option for Rheumatoid Arthritis. Pharmaceutics. 2022;14:1681. doi: 10.3390/pharmaceutics14081681.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14081681</ArticleId><ArticleId IdType="pmc">PMC9416659</ArticleId><ArticleId IdType="pubmed">36015308</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter R.M., Young M.K., Petri W.A.O., Lyons G.R., Gilchrist C., Carey R.M., Petri W.A. Repressed Ang 1&#x2013;7 in COVID-19 Is Inversely Associated with Inflammation and Coagulation. mSphere. 2022;7:e00220-22. doi: 10.1128/msphere.00220-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/msphere.00220-22</ArticleId><ArticleId IdType="pmc">PMC9429950</ArticleId><ArticleId IdType="pubmed">35913134</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry B.M., Benoit J.L., Berger B.A., Pulvino C., Lavie C.J., Lippi G., Benoit S.W. Coronavirus disease 2019 is associated with low circulating plasma levels of angiotensin 1 and angiotensin 1, 7. J. Med. Virol. 2021;93:678&#x2013;680. doi: 10.1002/jmv.26479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26479</ArticleId><ArticleId IdType="pubmed">32880990</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Yang Y., Zhang C., Huang F., Wang F., Yuan J., Wang Z., Li J., Li J., Feng C., et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci. China Life Sci. 2020;63:364&#x2013;374. doi: 10.1007/s11427-020-1643-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11427-020-1643-8</ArticleId><ArticleId IdType="pmc">PMC7088566</ArticleId><ArticleId IdType="pubmed">32048163</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z., Hu R., Zhang C., Ren W., Yu A., Zhou X. Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients. Crit. Care. 2020;24:290. doi: 10.1186/s13054-020-03015-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03015-0</ArticleId><ArticleId IdType="pmc">PMC7273814</ArticleId><ArticleId IdType="pubmed">32503680</ArticleId></ArticleIdList></Reference><Reference><Citation>Pucci F., Annoni F., dos Santos R.A.S., Taccone F.S., Rooman M. Quantifying Renin-Angiotensin-System Alterations in COVID-19. Cells. 2021;10:2755. doi: 10.3390/cells10102755.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10102755</ArticleId><ArticleId IdType="pmc">PMC8535134</ArticleId><ArticleId IdType="pubmed">34685735</ArticleId></ArticleIdList></Reference><Reference><Citation>van Lier D., Kox M., Santos K., van der Hoeven H., Pillay J., Pickkers P. Increased blood angiotensin converting enzyme 2 activity in critically ill COVID-19 patients. ERJ Open Res. 2021;7:00848-2020. doi: 10.1183/23120541.00848-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00848-2020</ArticleId><ArticleId IdType="pmc">PMC7848790</ArticleId><ArticleId IdType="pubmed">33738305</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams P.B. Renin Angiotensin System Inhibition as treatment for Covid-19? eClinicalMedicine. 2021;37:101023. doi: 10.1016/j.eclinm.2021.101023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101023</ArticleId><ArticleId IdType="pmc">PMC8275567</ArticleId><ArticleId IdType="pubmed">34278280</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G., Xiao B., Deng J., Gong L., Li Y., Li J., Zhong Y. The Role of Cytochrome P450 Enzymes in COVID-19 Pathogenesis and Therapy. Front. Pharmacol. 2022;13:791922. doi: 10.3389/fphar.2022.791922.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.791922</ArticleId><ArticleId IdType="pmc">PMC8847594</ArticleId><ArticleId IdType="pubmed">35185562</ArticleId></ArticleIdList></Reference><Reference><Citation>Imig J.D. Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function. Adv. Pharmacol. 2016;77:105&#x2013;141. doi: 10.1016/bs.apha.2016.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.apha.2016.04.003</ArticleId><ArticleId IdType="pmc">PMC5510644</ArticleId><ArticleId IdType="pubmed">27451096</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G., Kodani S., Hammock B.D. Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer. Prog. Lipid Res. 2014;53:108&#x2013;123. doi: 10.1016/j.plipres.2013.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plipres.2013.11.003</ArticleId><ArticleId IdType="pmc">PMC3914417</ArticleId><ArticleId IdType="pubmed">24345640</ArticleId></ArticleIdList></Reference><Reference><Citation>Stading R., Couroucli X., Lingappan K., Moorthy B. The role of cytochrome P450 (CYP) enzymes in hyperoxic lung injury. Expert Opin. Drug Metab. Toxicol. 2021;17:171&#x2013;178. doi: 10.1080/17425255.2021.1853705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17425255.2021.1853705</ArticleId><ArticleId IdType="pmc">PMC7864879</ArticleId><ArticleId IdType="pubmed">33215946</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoff U., Bubalo G., Fechner M., Blum M., Zhu Y., Pohlmann A., Hentschel J., Arakelyan K., Seeliger E., Flemming B., et al. A synthetic epoxyeicosatrienoic acid analogue prevents the initiation of ischemic acute kidney injury. Acta Physiol. 2019;227:e13297. doi: 10.1111/apha.13297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apha.13297</ArticleId><ArticleId IdType="pmc">PMC6733619</ArticleId><ArticleId IdType="pubmed">31077555</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Ding A., Yang D., Cui T., Yang H., Zhang H., Wang C. CYP2J2-produced epoxyeicosatrienoic acids attenuate ischemia/reperfusion-induced acute kidney injury by activating the SIRT1-FoxO3a pathway. Life Sci. 2020;246:117327. doi: 10.1016/j.lfs.2020.117327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117327</ArticleId><ArticleId IdType="pubmed">31954161</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng J., Garcia V., Ding Y., Wu C.-C., Thakar K., Falck J.R., Ramu E., Schwartzman M.L. Induction of Angiotensin-Converting Enzyme and Activation of the Renin&#x2013;Angiotensin System Contribute to 20-Hydroxyeicosatetraenoic Acid&#x2013;Mediated Endothelial Dysfunction. Arterioscler. Thromb. Vasc. Biol. 2012;32:1917&#x2013;1924. doi: 10.1161/ATVBAHA.112.248344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.112.248344</ArticleId><ArticleId IdType="pmc">PMC3418056</ArticleId><ArticleId IdType="pubmed">22723444</ArticleId></ArticleIdList></Reference><Reference><Citation>Minuz P., Jiang H., Fava C., Turolo L., Tacconelli S., Ricci M., Patrignani P., Morganti A., Lechi A., McGiff J.C. Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. Hypertension. 2008;51:1379&#x2013;1385. doi: 10.1161/HYPERTENSIONAHA.107.105395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.107.105395</ArticleId><ArticleId IdType="pmc">PMC4544761</ArticleId><ArticleId IdType="pubmed">18378855</ArticleId></ArticleIdList></Reference><Reference><Citation>Sodhi K., Wu C.-C., Cheng J., Gotlinger K., Inoue K., Goli M., Falck J.R., Abraham N.G., Schwartzman M.L. CYP4A2-Induced Hypertension Is 20-Hydroxyeicosatetraenoic Acid&#x2013; and Angiotensin II&#x2013;Dependent. Hypertension. 2010;56:871&#x2013;878. doi: 10.1161/HYPERTENSIONAHA.110.154559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.110.154559</ArticleId><ArticleId IdType="pmc">PMC2995375</ArticleId><ArticleId IdType="pubmed">20837888</ArticleId></ArticleIdList></Reference><Reference><Citation>Rompe F., Artuc M., Hallberg A., Alterman M., Str&#xf6;der K., Th&#xf6;ne-Reineke C., Reichenbach A., Schacherl J., Dahl&#xf6;f B., Bader M., et al. Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension. 2010;55:924&#x2013;931. doi: 10.1161/HYPERTENSIONAHA.109.147843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.109.147843</ArticleId><ArticleId IdType="pubmed">20157051</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan Y., Wallinder C., Plouffe B., Beaudry H., Mahalingam A.K., Wu X., Johansson B., Holm M., Botoros M., Karl&#xe9;n A., et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J. Med. Chem. 2004;47:5995&#x2013;6008. doi: 10.1021/jm049715t.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm049715t</ArticleId><ArticleId IdType="pubmed">15537354</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L., Iwai M., Li Z., Shiuchi T., Min L.J., Cui T.X., Li J.M., Okumura M., Nahmias C., Horiuchi M. Regulation of inhibitory protein-kappaB and monocyte chemoattractant protein-1 by angiotensin II type 2 receptor-activated Src homology protein tyrosine phosphatase-1 in fetal vascular smooth muscle cells. Mol. Endocrinol. 2004;18:666&#x2013;678. doi: 10.1210/me.2003-0053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/me.2003-0053</ArticleId><ArticleId IdType="pubmed">14684844</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoll M., Steckelings U.M., Paul M., Bottari S.P., Metzger R., Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J. Clin. Investig. 1995;95:651&#x2013;657. doi: 10.1172/JCI117710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI117710</ArticleId><ArticleId IdType="pmc">PMC295531</ArticleId><ArticleId IdType="pubmed">7860748</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuzuki S., Matoba T., Eguchi S., Inagami T. Angiotensin II Type 2 Receptor Inhibits Cell Proliferation and Activates Tyrosine Phosphatase. Hypertension. 1996;28:916&#x2013;918. doi: 10.1161/01.HYP.28.5.916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.HYP.28.5.916</ArticleId><ArticleId IdType="pubmed">8901845</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Q., Miyazaki R., Ichiki T., Imayama I., Inanaga K., Ohtsubo H., Yano K., Takeda K., Sunagawa K. Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-gamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta. Hypertension. 2009;53:798&#x2013;804. doi: 10.1161/HYPERTENSIONAHA.108.126656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.108.126656</ArticleId><ArticleId IdType="pubmed">19289654</ArticleId></ArticleIdList></Reference><Reference><Citation>de Gasparo M., Catt K.J., Inagami T., Wright J.W., Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 2000;52:415&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">10977869</ArticleId></ArticleIdList></Reference><Reference><Citation>Steckelings U.M., Kaschina E., Unger T. The AT2 receptor--a matter of love and hate. Peptides. 2005;26:1401&#x2013;1409. doi: 10.1016/j.peptides.2005.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2005.03.010</ArticleId><ArticleId IdType="pubmed">16042980</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos R.A.S., e Silva A.C.S., Maric C., Silva D.M.R., Machado R.P., de Buhr I., Heringer-Walther S., Pinheiro S.V.B., Lopes M.T., Bader M., et al. Angiotensin-(1&#x2013;7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. USA. 2003;100:8258&#x2013;8263. doi: 10.1073/pnas.1432869100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1432869100</ArticleId><ArticleId IdType="pmc">PMC166216</ArticleId><ArticleId IdType="pubmed">12829792</ArticleId></ArticleIdList></Reference><Reference><Citation>Das U.N. Can Bioactive Lipids Inactivate Coronavirus (COVID-19)? Arch. Med. Res. 2020;51:282&#x2013;286. doi: 10.1016/j.arcmed.2020.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2020.03.004</ArticleId><ArticleId IdType="pmc">PMC7270578</ArticleId><ArticleId IdType="pubmed">32229155</ArticleId></ArticleIdList></Reference><Reference><Citation>Smeitink J., Jiang X., Pecheritsyna S., Renkema H., van Maanen R., Beyrath J. Hypothesis: mPGES-1-Derived Prostaglandin E2, a So Far Missing Link in COVID-19 Pathophysiology? Preprints Org. 2020:2020040180. doi: 10.20944/preprints202004.0180.v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.20944/preprints202004.0180.v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Malacarne P.F., Bezzenberger J., Lopez M., Warwick T., M&#xfc;ller N., Brandes R.P., Rezende F. Epoxyeicosatrienoic Acid and Prostanoid Crosstalk at the Receptor and Intracellular Signaling Levels to Maintain Vascular Tone. Int. J. Mol. Sci. 2022;23:5939. doi: 10.3390/ijms23115939.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23115939</ArticleId><ArticleId IdType="pmc">PMC9180422</ArticleId><ArticleId IdType="pubmed">35682616</ArticleId></ArticleIdList></Reference><Reference><Citation>Pace S., Rossi A., Krauth V., Dehm F., Troisi F., Bilancia R., Weinigel C., Rummler S., Werz O., Sautebin L. Sex differences in prostaglandin biosynthesis in neutrophils during acute inflammation. Sci. Rep. 2017;7:3759. doi: 10.1038/s41598-017-03696-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-03696-8</ArticleId><ArticleId IdType="pmc">PMC5476623</ArticleId><ArticleId IdType="pubmed">28630405</ArticleId></ArticleIdList></Reference><Reference><Citation>Fain J.N., Kanu A., Bahouth S.W., Cowan G.S.M., Hiler M.L., Leffler C.W. Comparison of PGE2, prostacyclin and leptin release by human adipocytes versus explants of adipose tissue in primary culture. Prostaglandins Leukot. Essent. Fat. Acids. 2002;67:467&#x2013;473. doi: 10.1054/plef.2002.0430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1054/plef.2002.0430</ArticleId><ArticleId IdType="pubmed">12468269</ArticleId></ArticleIdList></Reference><Reference><Citation>Fayed M., Patel N., Angappan S., Nowak K., Vasconcelos Torres F., Penning D.H., Chhina A.K. Sequential Organ Failure Assessment (SOFA) Score and Mortality Prediction in Patients With Severe Respiratory Distress Secondary to COVID-19. Cureus. 2022;14:e26911. doi: 10.7759/cureus.26911.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.26911</ArticleId><ArticleId IdType="pmc">PMC9290429</ArticleId><ArticleId IdType="pubmed">35865183</ArticleId></ArticleIdList></Reference><Reference><Citation>de Girolamo L., Peretti G.M., Maffulli N., Brini A.T. Covid-19&#x2014;The real role of NSAIDs in Italy. J. Orthop. Surg. Res. 2020;15:165. doi: 10.1186/s13018-020-01682-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13018-020-01682-x</ArticleId><ArticleId IdType="pmc">PMC7197233</ArticleId><ArticleId IdType="pubmed">32366317</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushner P., McCarberg B.H., Grange L., Kolosov A., Haveric A.L., Zucal V., Petruschke R., Bissonnette S. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in COVID-19. NPJ Prim. Care Respir. Med. 2022;32:35. doi: 10.1038/s41533-022-00300-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41533-022-00300-z</ArticleId><ArticleId IdType="pmc">PMC9489480</ArticleId><ArticleId IdType="pubmed">36127354</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J.S., Alfajaro M.M., Chow R.D., Wei J., Filler R.B., Eisenbarth S.C., Wilen C.B. Nonsteroidal Anti-inflammatory Drugs Dampen the Cytokine and Antibody Response to SARS-CoV-2 Infection. J. Virol. 2021;95:e00014-21. doi: 10.1128/JVI.00014-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00014-21</ArticleId><ArticleId IdType="pmc">PMC8092681</ArticleId><ArticleId IdType="pubmed">33441348</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelleni M.T. NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: Potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects. Expert Rev. Anti Infect. Ther. 2022;20:17&#x2013;21. doi: 10.1080/14787210.2021.1939683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2021.1939683</ArticleId><ArticleId IdType="pmc">PMC8220441</ArticleId><ArticleId IdType="pubmed">34088250</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravichandran R., Mohan S.K., Sukumaran S.K., Kamaraj D., Daivasuga S.S., Ravi S.O.A.S., Vijayaraghavalu S., Kumar R.K. An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised COVID-19 patients. Sci. Rep. 2022;12:6413. doi: 10.1038/s41598-022-10370-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-10370-1</ArticleId><ArticleId IdType="pmc">PMC9016692</ArticleId><ArticleId IdType="pubmed">35440611</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosentino M., Vernocchi V., Martini S., Marino F., Allasino B., B&#xe0;lzola M.A., Burigana F., Dallari A., Pagano C.S.F., Palma A., et al. Early Outpatient Treatment of COVID-19: A Retrospective Analysis of 392 Cases in Italy. J. Clin. Med. 2022;11:6138. doi: 10.3390/jcm11206138.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11206138</ArticleId><ArticleId IdType="pmc">PMC9605012</ArticleId><ArticleId IdType="pubmed">36294461</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman-Esquivel J., Galvan-Salazar H.R., Guzman-Solorzano H.P., Cuevas-Velazquez A.C., Guzman-Solorzano J.A., Mokay-Ramirez K.A., Paz-Michel B.A., Murillo-Zamora E., Delgado-Enciso J., Melnikov V., et al. Efficacy of the use of mefenamic acid combined with standard medical care vs. standard medical care alone for the treatment of COVID-19: A randomized double-blind placebo-controlled trial. Int. J. Mol. Med. 2022;49:29. doi: 10.3892/ijmm.2022.5084.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2022.5084</ArticleId><ArticleId IdType="pubmed">35029292</ArticleId></ArticleIdList></Reference><Reference><Citation>Suter F., Consolaro E., Pedroni S., Moroni C., Past&#xf2; E., Paganini M.V., Pravettoni G., Cantarelli U., Rubis N., Perico N., et al. A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: A retrospective observational matched-cohort study. eClinicalMedicine. 2021;37:100941. doi: 10.1016/j.eclinm.2021.100941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.100941</ArticleId><ArticleId IdType="pmc">PMC8189543</ArticleId><ArticleId IdType="pubmed">34127959</ArticleId></ArticleIdList></Reference><Reference><Citation>Consolaro E., Suter F., Rubis N., Pedroni S., Moroni C., Past&#xf2; E., Paganini M.V., Pravettoni G., Cantarelli U., Perico N., et al. A Home-Treatment Algorithm Based on Anti-inflammatory Drugs to Prevent Hospitalization of Patients With Early COVID-19: A Matched-Cohort Study (COVER 2) Front. Med. 2022;9:785785. doi: 10.3389/fmed.2022.785785.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.785785</ArticleId><ArticleId IdType="pmc">PMC9073076</ArticleId><ArticleId IdType="pubmed">35530041</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>